Helping scientists investigate the unanswered
We will consider providing financial support and/or product supply for novel research proposals that answer important scientific and medical questions in our areas of interest. Grant recipients have the right to publish the results of the study and maintain full control over the research project objectives, design, conduct, data analysis, and interpretation.
Contact us with any questions about requirements and procedures
Submit a request for grant support
Areas of interest
Amikacin Liposome Inhalation Suspension and Pulmonary Infections
Interventional Amikacin Liposome Inhalation Suspension in Nontuberculous Mycobacterial (NTM) Lung Disease
- NTM in different population
- By disease severity (e.g., using a severity index)
- By species
- Transplant population – pre- and post-transplant
- Mixed NTM infection
- Cavitary disease
- Assessment of disease
- Biomarkers and genetic markers for NTM diagnosis and disease progression
- Radiographic change and disease response to amikacin liposome inhalation suspension
- Culture assessment
- Adverse event management/medication adherence
Amikacin Liposome Inhalation Suspension in Non-NTM Pulmonary Infections
- Gram-negative infections
- Acute pneumonia (ventilator-associated pneumonia)
- Multi-drug resistant tuberculosis (MTB or MDR-TB)
Disease State/Mechanism of Disease
- Novel models of infection
- Understanding relapse/reinfection
Burden of Illness of NTM Lung Disease
- Indirect costs of NTM lung disease
- Impact of NTM lung disease on patient functioning and productivity
- Epidemiology of Mycobacterium avium complex (MAC) and Mycobacterium abscessus (MAB) infections
- Barriers to appropriate and timely screening of NTM lung disease
- Barriers to appropriate guideline-based treatment initiation and treatment adherence with treatment for NTM lung disease
Bronchiectasis and Other Neutrophil-Related Disorders
Disease State/Mechanism of Disease
- Neutrophil-related pulmonary disease
- Levels of neutrophil serine protease (NSP) biomarkers of disease severity/burden in patients with autoimmune or inflammatory disease
- Natural history, clinical course, and progression of the disease
